Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis

OBJECTIVES: To examine whether treatment with anti‐tumour necrosis factor (TNF) α prevents loss of bone mineral density (BMD) at the spine and hip (generalised) and in the hands (local) of patients with rheumatoid arthritis, and to study the changes in markers of bone metabolism, including receptor...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Vis, M, Havaardsholm, E A, Haugeberg, G, Uhlig, T, Voskuyl, A E, van de Stadt, R J, Dijkmans, B A C, Woolf, A D, Kvien, T K, Lems, W F
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Group 2006
Ämnen:
Extended Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798341/
https://ncbi.nlm.nih.gov/pubmed/16606653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2005.044198
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk